Bepotastine besilate for the treatment of pruritus

Bielory, Leonard; Duttachoudhury, Shubhasree; McMunn, Andrea

doi:10.1517/14656566.2013.849242

Cited by 11 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These agents provide the benefits of two classes of drugs: the immediate relief of antihistamines with the prophylactic benefit of mast cell stabilizers, and as well some have been shown to have other actions including inhibition of eosinophil migration and other mediators of inflammation (e.g. IL-5, PAF, LTB4) [47]. These are used to ameliorate symptoms but may be augmented by other treatments (e.g.…”

Section: Topical Dual-activity Agents (Antihistamine/mast-cell Stabilmentioning

confidence: 99%

A contemporary look at allergic conjunctivitis

Dupuis

Prokopich

Hynes³

et al. 2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Allergic eye disease is common, yet often overlooked in North America. In the U.S., up to 40% of the population is deemed to be affected and this number is growing. Symptoms and signs of ocular allergy can lead to decreased productivity and negatively impact quality of life (QoL). Various treatment options exist to achieve symptom control. For allergic conjunctivitis, ophthalmic agents include antihistamines, mast cell stabilizers, dual-activity agents, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and some off-label treatments. Immunotherapy is recommended as a therapeutic option. This review provides a summary of the forms of ocular allergies, with a focus on symptoms and signs, impact on QoL, physical examination, diagnosis and therapeutic options of allergic conjunctivitis. Through multidisciplinary collaborations, a simplified algorithm for the treatment of allergic conjunctivitis is proposed for Canadian clinical practice.

show abstract

Section: Topical Dual-activity Agents (Antihistamine/mast-cell Stabilmentioning

confidence: 99%

A contemporary look at allergic conjunctivitis

Dupuis

Prokopich

Hynes³

et al. 2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Dual action agents group includes drugs such as Olopatadine, Ketotifen, Bepotastine, Alcaftadine and Azelastine which act both as H1 antihistamines and MC stabilizers. Some of these drugs have multiple action and immunological effects, for instance, Bepotastine may have a role in inhibition of eosinophil migration, IL‐5, leukotrienes (e.g, LTB4) and PAF . Additional properties of Alcaftadine include H2 and H4 receptor inverse agonism, inhibition of MC histamine release, decreased eosinophil chemotaxis and activation .…”

Section: Treatment Of Allergic Conjunctivitismentioning

confidence: 99%

Clinical implications of mast cell involvement in allergic conjunctivitis

Komi

Rambasek

Bielory

2017

Allergy

View full text Add to dashboard Cite

The conjunctiva is a common site for the allergic inflammatory response due to it being highly vascularized, having constant exposure to environmental pollutants and allergenic pollens and having a unique conjunctival associated lymphoid tissue. The primary morbidity of anterior surface conjunctival disorders that include allergic conjunctivitis and tear film disorders is associated with its high frequency of involvement rather than its severity, although the more chronic forms can involve the cornea and lead to sight-threatening conditions. Ocular allergy is associated with IgE-mediated mast cell activation in conjunctival tissue leading to the release of pre- The allergic events during AC occur following exposure to allergens mainly pollens, animal dander, and mold spores. Mast cell activation takes place in two phases: an acute phase, occurring within minutes, and a late phase, spanning from 6 to 72 h after exposure. The acute-phase reaction is due to the release of preformed (e.g,

show abstract

“…Bepotastine 1.5% (Bepreve) is the newest of the FDA-approved ophthalmic antihistamines. 68,69 Ketotifen. 58,64,65 Pretreatment by bepotastine differentially reduced IL-5 as well as itching associated with LTB-4 injection in an animal model.…”

Section: Secondary Intervention -A Step Approach 47mentioning

confidence: 99%